Digestive Diseases and Sciences

, Volume 52, Issue 9, pp 2292–2300 | Cite as

Stem Cell Factor/c-kit Receptor Signaling Enhances the Proliferation and Invasion of Colorectal Cancer Cells Through the PI3K/Akt Pathway

  • Akira YasudaEmail author
  • Hirozumi Sawai
  • Hiroki Takahashi
  • Nobuo Ochi
  • Yoichi Matsuo
  • Hitoshi Funahashi
  • Mikinori Sato
  • Yuji Okada
  • Hiromitsu Takeyama
  • Tadao Manabe
Original Paper


In this study, we examined the role of c-kit receptor (KIT) signal transduction on the proliferation and invasion of colorectal cancer cells. We found that c-kit was expressed in 2 colorectal cancer cell lines as determined by RT-PCR, Western blot, and flow cytometry. In KIT-positive lines, KIT was activated by stem cell factor (SCF). SCF enhanced cellular proliferation of positive lines as demonstrated by the WST-1 proliferation assay. Furthermore, SCF enhanced the invasive ability of KIT-positive cell lines. SCF stimulation upregulated p44/42 mitogen-activated protein kinase (MAPK) and Akt as shown by Western blot. We examined the roles played by p44/42 MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt pathways in proliferation and invasion. PI3K/Akt activity strongly correlated with proliferation and invasion and p44/42 MAPK was correlated with only invasion. In conclusion, the SCF-enhanced proliferation and invasion of KIT-positive colorectal cancer cells is achieved mainly through the PI3K/Akt pathway.


c-kit SCF Colorectal cancer PI3K/Akt Proliferation Invasion 


  1. 1.
    Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A (1987) Human proto-oncogene c-kit: a new surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341–3351PubMedGoogle Scholar
  2. 2.
    Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Mrdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV (1990) Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213–224PubMedCrossRefGoogle Scholar
  3. 3.
    Williams DE, Eisenman J, Baird A, Rauch C, Ness KV, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, Burgess GS, Cosman D, Lyman SD (1990) Identification of a ligand for the c-kit proto-oncogene. Cell 63:167–174PubMedCrossRefGoogle Scholar
  4. 4.
    Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P (1990) The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of c-kit receptor, the gene product of the W locus. Cell 63:225–233PubMedCrossRefGoogle Scholar
  5. 5.
    Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Helden CH (1991) Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 10:4121–4128PubMedGoogle Scholar
  6. 6.
    Ashman LK (1999) The biology of stem cell factor and its receptor c-kit. Int J Biochem 31:1037–1051Google Scholar
  7. 7.
    Hulzinga JD, Thuneberg L, Klüpel M, Malysz J, Mikkelsen HB, Bernstein A (1985) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347–349CrossRefGoogle Scholar
  8. 8.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurarta A, Takeda M, Muhammad T, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580PubMedCrossRefGoogle Scholar
  9. 9.
    Naeem M, Dahiya M, Clark JI, Clark JI, Creech SD, Alkan S (2002) Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 33:1182–1187PubMedCrossRefGoogle Scholar
  10. 10.
    Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, Kuramoto A, Satow Y (1995) c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 91:661–663PubMedGoogle Scholar
  11. 11.
    Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugihara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92:1736–1744PubMedCrossRefGoogle Scholar
  12. 12.
    Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS (2004) Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10:3076–3081PubMedCrossRefGoogle Scholar
  13. 13.
    Karin M (1992) Signal transduction form cell surface to nucleus in development and disease. FASEB J 6:2581–2590PubMedGoogle Scholar
  14. 14.
    Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788PubMedCrossRefGoogle Scholar
  15. 15.
    Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484–495PubMedCrossRefGoogle Scholar
  16. 16.
    Roskoski R Jr (2005) Structure and regulation of Kit protein-tyrosine kinase-The stem cell factor receptor. Biochem Biophys Res Commun 338:1307–1315PubMedCrossRefGoogle Scholar
  17. 17.
    Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyrer T, Zimmermann J (2002) Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 38 Suppl 5:S19–27PubMedCrossRefGoogle Scholar
  18. 18.
    Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K, Yachi A (1993) Expression of c-kit and kit Ligand in Human Colon Carcinoma Cells. Tumour Biol 14:295–302PubMedCrossRefGoogle Scholar
  19. 19.
    Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodeck U (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J Cell Physiol 172:1–11PubMedCrossRefGoogle Scholar
  20. 20.
    Sammarco I, Capurso G, Coppola L, Bonifazi AP, Cassetta S, Fave GD, Carrara A, Grassi GB, Rossi P, Sette C, Geremmia R (2004) Expression of the proto-oncogene c-kit in normal and tumor tissues from colorectal carcinoma patients. Int J Colorectal Dis 19:545–553PubMedCrossRefGoogle Scholar
  21. 21.
    Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, Martone T, Gramigni C, Camandona M, Emanuelli G, Rodeck U (2001) Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res 61:2200–2206PubMedGoogle Scholar
  22. 22.
    Bellone G, Ferrero D, Carbone A, De Quadros MR, Gramigni C, Prati A, Davidson W, Mioli P, Dughera L, Emanuelli G, Rodeck U (2004) Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther 3:385–392PubMedGoogle Scholar
  23. 23.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, Andre T, Mareel M, Mester J, Gespach C (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62:4879–4883PubMedGoogle Scholar
  24. 24.
    Langley KE, Bennett LG, Wypych J, Yancik SA, Liu XD, Westcott KR, Chang DG, Smith KA, Zsebo KM (1993) Soluble stem cell factor in human serum. Blood 81:656–660PubMedGoogle Scholar
  25. 25.
    Kitoh T, Ishikawa H, Ishii T, Nakagawa S (1998) Elevated SCF levels in the serum of patients with chronic renal failure. Br J Haematol 102:1151–1156PubMedCrossRefGoogle Scholar
  26. 26.
    Kitamura Y, Hirota S (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61:2924–2931PubMedCrossRefGoogle Scholar
  27. 27.
    Li J, Kleeff J, Guo J, Fischer L, Giese N, Buchler MW, Friess H (2003) Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2:32PubMedCrossRefGoogle Scholar
  28. 28.
    Wang WS, Chen PM, Su Y (2006) Colorectal carcinoma: from tumorigenesis to treatment. Cell Mol Life Sci 63:663–671PubMedCrossRefGoogle Scholar
  29. 29.
    Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27:684–694PubMedCrossRefGoogle Scholar
  30. 30.
    Whisenant J, Bergsland E (2005) Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol 6:411–421PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Akira Yasuda
    • 1
    Email author
  • Hirozumi Sawai
    • 1
  • Hiroki Takahashi
    • 1
  • Nobuo Ochi
    • 1
  • Yoichi Matsuo
    • 1
  • Hitoshi Funahashi
    • 1
  • Mikinori Sato
    • 1
  • Yuji Okada
    • 1
  • Hiromitsu Takeyama
    • 1
  • Tadao Manabe
    • 1
  1. 1.Department of Gastroenterological SurgeryNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations